hotspot -WSS

hotspot

author：hotspot 2025-09-05 11:24:54 - browse：3

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： First over

WSS

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medicare drug price negotiation hearing pits pharma v Biden admin

Longer MASH drug regimen improved liver, Akero study finds

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Florida health officials providing scant details on measles cases

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

hotspot

knowledge

Continuity nursing helped my family in our darkest PICU moments

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Virginia high school admissions case could be legal follow

First over

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves Moderna’s RSV vaccine, its second licensed product

How one medical school became remarkably diverse

Medicare Advantage's lean provider networks lead CMS complaints

In Memoriam: Notable people who died in 2023

Structure Therapeutics oral GLP

leisure time

Pregnant women don't need prenatal multivitamins, study concludes

How CO2 helps viruses stay alive longer in the air

BD to buy Edwards patient monitoring unit for $4.2 billion

Senators tussle over abortion against the backdrop of a presidential campaign

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Ancient Greek ideas underpin modern concepts of pregnancy

explore

hotspot

explore

knowledge